AFFiRiS AG, a Vienna, Austria-based developer of tailor-made peptide vaccines for Alzheimer’s disease, Atherosclerosis, Parkinson’s disease, hypertension and several other conditions, has raised €25m in equity funding.
Backers include Santo VC GmbH, which committed €20m, as well as existing investor MIG funds, which increased its stake in the company by €5m through its MIG 11 fund. Both Santo VC and MIG have secured an option to extend their stake in AFFiRiS by a further combined €30m.
AFFiRiS intends to use the capital to advance its wide-ranging clinical development programme.
Co-founded by CEO Walter Schmidt and CSO Frank Mattner, the company has Alzheimer’s disease as its current lead indication. It currently employs 83 staff at the Campus Vienna Biocenter.
FinSMEs
09/11/2011